Scarica l'app Stockscreener
113.81
0.40%
0.45
Dopo l'orario di chiusura:
113.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales - Yahoo Finance
Incyte Corp gains 16% in a week, boosted by str... - Pluang
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura - Yahoo Finance
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
H.C. Wainwright reiterates Incyte stock rating on EU label expansion By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Incyte stock rating on EU label expansion - Investing.com
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now - Yahoo Finance
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs - Yahoo Finance
INCY Maintains by UBS -- Price Target Raised to $113 - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
UBS raises Incyte stock price target to $113 on biotech recovery By Investing.com - Investing.com Australia
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com Nigeria
Why is Incyte stock surging today? - Investing.com
Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis - grafa.com
Incyte (INCY) Receives Positive CHMP Opinion for Opzelura Approval - GuruFocus
Incyte Corporation stock hits 52-week high at 112.32 USD - Investing.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - BioSpace
Incyte stock jumps on positive EU review for eczema cream - Investing.com
Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight - Stock Titan
(ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis - Business Wire
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte extends hematology data at EHA, shares track NASDAQ biotech peers - Ad-hoc-news.de
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
INCY Maintained by Truist Securities -- Price Target Raised to $105 - GuruFocus
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Sahm
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
INCY Upgraded by BMO Capital -- Price Target Raised to $94.00 - GuruFocus
Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules - StreetInsider
Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling - TradingView
BMO upgrades Incyte stock rating on strategic progress By Investing.com - Investing.com South Africa
Incyte Stock: Is INCY Outperforming the Healthcare Sector? - Barchart.com
BMO upgrades Incyte stock rating on strategic progress - Investing.com
Incyte (INCY) Secures Approval for Minjuvi in Japan - GuruFocus
Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo
Incyte StockStifel lifts price target after bile duct disease data - AD HOC NEWS
0.93%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):